What is the intrinsic value of PTGX?
As of 2026-10-03, the Intrinsic Value of Protagonist Therapeutics Inc (PTGX) is
32.23 USD. This PTGX valuation is based on the model Peter Lynch Fair Value.
With the current market price of 140.06 USD, the upside of Protagonist Therapeutics Inc is
-76.99%.
Is PTGX undervalued or overvalued?
Based on its market price of 140.06 USD and our intrinsic valuation, Protagonist Therapeutics Inc (PTGX) is overvalued by 76.99%.
32.23 USD
Intrinsic Value
PTGX Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(735.14) - (63.50) |
(118.48) |
-184.6% |
| DCF (Growth 10y) |
(62.87) - (671.62) |
(112.83) |
-180.6% |
| DCF (EBITDA 5y) |
(31.77) - (38.25) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(35.63) - (43.36) |
(1,234.50) |
-123450.0% |
| Fair Value |
32.23 - 32.23 |
32.23 |
-76.99% |
| P/E |
32.23 - 50.15 |
39.58 |
-71.7% |
| EV/EBITDA |
19.52 - 27.87 |
24.00 |
-82.9% |
| EPV |
6.81 - 6.87 |
6.84 |
-95.1% |
| DDM - Stable |
18.19 - 87.00 |
52.60 |
-62.4% |
| DDM - Multi |
(23.66) - (89.00) |
(37.50) |
-126.8% |
PTGX Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
9,007.26 |
| Beta |
-0.64 |
| Outstanding shares (mil) |
64.31 |
| Enterprise Value (mil) |
8,587.18 |
| Market risk premium |
4.60% |
| Cost of Equity |
6.91% |
| Cost of Debt |
5.00% |
| WACC |
5.29% |